Former FDA Senior Official Michael Chappell Joins Greenleaf Health LLC

Emirates PharmaAdvertisement

Greenleaf Health LLC today announced that Michael Chappell, former Acting Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (“FDA”), has joined the firm as Senior Advisor. Greenleaf Health is a full service regulatory consulting firm that provides strategic guidance to companies regulated by the FDA and those developing innovative solutions to pressing public health challenges around the globe.

In his new role, Chappell will work with Greenleaf clients to provide strategic consulting services on regulatory, enforcement and compliance matters. Chappell joins Greenleaf following a distinguished 38-year career in FDA’s Office of Regulatory Affairs (“ORA”).

Prior to joining Greenleaf, Chappell served as FDA’s Acting Associate Commissioner for Regulatory Affairs and Deputy Associate Commissioner for Field Operations from 2007 – 2010. In this role, he was head of a 4,000-person staff spanning five regional offices that are responsible for imports, inspections and enforcement policy.

Previously, Chappell served as director of the Dallas District where he was responsible for all FDA domestic field activities in Texas, Oklahoma and Arkansas. He was also a supervisory consumer safety officer in the Atlanta District and a director of investigations for the Florida District, where he managed all field investigational programs for the district and one of the largest import operations in FDA’s Southeast Region.

Mr. Chappell started his FDA career as a consumer safety officer in Nashville. He later became the resident in charge of the Memphis Resident Post of the Nashville District, where he was responsible for new emphasis programs for the field force in medical devices, biologics, and bioresearch. Mr. Chappell is a graduate of the University of Alabama.

Greenleaf Health LLC. is a full service regulatory consulting firm that provides strategic guidance to companies developing innovative solutions to pressing public health challenges around the globe and to a select group of healthcare sector clients, including pharmaceutical, biotechnology and medical device companies whose activities are regulated by the FDA. For more information on Michael Chappell or Greenleaf Health, please visit www.greenleafhealthllc.com.

 

 

Emirates PharmaAdvertisement